Advertisement

European Radiology

, Volume 28, Issue 4, pp 1345–1355 | Cite as

Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: A prospective study

  • Sharon S. Brouha
  • Phirum Nguyen
  • Ricki Bettencourt
  • Claude B. Sirlin
  • Rohit Loomba
Cardiac

Abstract

Objectives

To determine whether severity of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis quantitatively assessed in individuals with diabetes mellitus (DM)-2 correlate with increased coronary heart disease (CHD) risk using non-invasive markers.

Methods

We conducted a single-centre, prospective, cross-sectional study in 100 consecutive diabetic individuals without known CHD recruited between March 2013 and September 2014. History, physical examination, serum markers, cardiac computed tomography (CT), magnetic resonance (MR) imaging-estimated proton density fat fraction (PDFF) and MR elastography (MRE) were obtained for 95 participants. Written informed consent was provided. Institutional review board approved this study. Spearman rank correlation was performed to assess for correlations. Multiple linear regression model determined independent predictors of epicardial adipose tissue (EAT) volume.

Results

A p value < 0.05 determined statistical significance. The EAT volume was higher in the NAFLD group, defined as MR-imaging PDFF ≥ 5 %, compared to the non-NAFLD group (126.5 ml (IQR 80.9) versus 85.4 ml (IQR 44.7), p=0.002). MR imaging-PDFF correlated with EAT (r=0.42, p < 0.0001). MR imaging-PDFF and liver fibrosis were independently associated with EAT.

Conclusions

Higher liver fat content and liver fibrosis may portend worse cardiovascular risk in diabetics.

Key Points

EAT volume is higher in diabetic individuals with NAFLD.

Liver fat content is positively correlated with EAT.

Liver fat content and liver fibrosis were independently associated with EAT.

Higher liver fat content and fibrosis may adversely affect cardiovascular risk.

Keywords

Non-alcoholic fatty liver disease Liver fibrosis Magnetic resonance imaging Coronary disease Multidetector computed tomography 

Abbreviations

CAC

Coronary artery calcium

CHD

Coronary heart disease

CT

Computed tomography

DM

Diabetes mellitus

EAT

Epicardial adipose tissue

MR

Magnetic resonance

MRE

Magnetic resonance elastography

NAFLD

Non-alcoholic fatty liver disease

PDFF

Proton density fat fraction

Notes

Funding

This study has received funding by the following:

• American Gastroenterological Association (AGA) Foundation—Sucampo—ASP Designated Research Award in Geriatric Gastroenterology

• T. Franklin Williams Scholarship Award

• Atlantic Philanthropies, Inc

• The John A. Hartford Foundation

• The Association of Specialty Professors

• American Gastroenterological Association

• Grant K23-DK090303

• Grant R01-DK106419-01.

• National Institute of Environmental Health Sciences of the National Institutes of Health under Award Number P42ES010337

Compliance with ethical standards

Guarantor

The scientific guarantor of this publication is Rohit Loomba MD MHSc.

Conflict of interest

The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.

Statistics and biometry

One of the authors has significant statistical expertise.

Informed consent

Written informed consent was obtained from all subjects (patients) in this study.

Ethical approval

Institutional Review Board approval was obtained.

Study subjects or cohorts overlap

Some study subjects or cohorts have been previously reported in the following:

Doycheva I, Cui J, Nguyen P, et al. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2016;43(1):83-95.

Methodology

• Prospective

• Cross-sectional study

• Performed at one institution

References

  1. 1.
    Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34:274–285CrossRefPubMedGoogle Scholar
  2. 2.
    Targher G, Day CP, Bonora E (2010) Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363:1341–1350CrossRefPubMedGoogle Scholar
  3. 3.
    Idilman IS, Akata D, Hazirolan T, Doganay Erdogan B, Aytemir K, Karcaaltincaba M (2015) Nonalcoholic fatty liver disease is associated with significant coronary artery disease in type 2 diabetic patients: a computed tomography angiography study 2. J Diabetes 7:279–286CrossRefPubMedGoogle Scholar
  4. 4.
    Targher G, Bertolini L, Padovani R et al (2007) Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30:1212–1218CrossRefPubMedGoogle Scholar
  5. 5.
    Targher G, Bertolini L, Rodella S et al (2007) Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 30:2119–2121CrossRefPubMedGoogle Scholar
  6. 6.
    McKimmie RL, Daniel KR, Carr JJ et al (2008) Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. Am J Gastroenterol 103:3029–3035CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Lautamaki R, Borra R, Iozzo P et al (2006) Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 291:E282–E290CrossRefPubMedGoogle Scholar
  8. 8.
    VanWagner LB, Ning H, Lewis CE et al (2014) Associations between nonalcoholic fatty liver disease and subclinical atherosclerosis in middle-aged adults: the Coronary Artery Risk Development in Young Adults Study. Atherosclerosis 235:599–605CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chen CH, Nien CK, Yang CC, Yeh YH (2010) Association between nonalcoholic fatty liver disease and coronary artery calcification. Dig Dis Sci 55:1752–1760CrossRefPubMedGoogle Scholar
  10. 10.
    Al Rifai M, Silverman MG, Nasir K et al (2015) The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 239:629–633CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Chhabra R, O'Keefe JH, Patil H et al (2013) Association of coronary artery calcification with hepatic steatosis in asymptomatic individuals. Mayo Clin Proc 88:1259–1265CrossRefPubMedGoogle Scholar
  12. 12.
    Lee YH, Wu YJ, Liu CC et al (2011) The severity of Fatty liver disease relating to metabolic abnormalities independently predicts coronary calcification. Radiol Res Pract 2011:586785PubMedPubMedCentralGoogle Scholar
  13. 13.
    Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC (2004) Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 291:210–215CrossRefPubMedGoogle Scholar
  14. 14.
    Petta S, Argano C, Colomba D et al (2015) Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. J Hepatol 62:928–933CrossRefPubMedGoogle Scholar
  15. 15.
    Sung KC, Wild SH, Kwag HJ, Byrne CD (2012) Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people. Diabetes Care 35:2359–2364CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kwak MS, Yim JY, Kim D et al (2015) Nonalcoholic fatty liver disease is associated with coronary artery calcium score in diabetes patients with higher HbA1c. Diabetol Metab Syndr 7:28CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Spearman JV, Renker M, Schoepf UJ et al (2015) Prognostic value of epicardial fat volume measurements by computed tomography: a systematic review of the literature. Eur Radiol.  https://doi.org/10.1007/s00330-015-3765-5
  18. 18.
    Mahabadi AA, Berg MH, Lehmann N et al (2013) Association of epicardial fat with cardiovascular risk factors and incident myocardial infarction in the general population: the Heinz Nixdorf Recall Study. J Am Coll Cardiol 61:1388–1395CrossRefPubMedGoogle Scholar
  19. 19.
    Arita Y, Kihara S, Ouchi N et al (2002) Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105:2893–2898CrossRefPubMedGoogle Scholar
  20. 20.
    Hirata Y, Kurobe H, Akaike M et al (2011) Enhanced inflammation in epicardial fat in patients with coronary artery disease. Int Heart J 52:139–142CrossRefPubMedGoogle Scholar
  21. 21.
    Hirata Y, Tabata M, Kurobe H et al (2011) Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue. J Am Coll Cardiol 58:248–255CrossRefPubMedGoogle Scholar
  22. 22.
    Laine P, Kaartinen M, Penttila A, Panula P, Paavonen T, Kovanen PT (1999) Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation 99:361–369CrossRefPubMedGoogle Scholar
  23. 23.
    Mazurek T, Zhang L, Zalewski A et al (2003) Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 108:2460–2466CrossRefPubMedGoogle Scholar
  24. 24.
    Mahabadi AA, Reinsch N, Lehmann N et al (2010) Association of pericoronary fat volume with atherosclerotic plaque burden in the underlying coronary artery: a segment analysis. Atherosclerosis 211:195–199CrossRefPubMedGoogle Scholar
  25. 25.
    Alexopoulos N, McLean DS, Janik M, Arepalli CD, Stillman AE, Raggi P (2010) Epicardial adipose tissue and coronary artery plaque characteristics. Atherosclerosis 210:150–154CrossRefPubMedGoogle Scholar
  26. 26.
    Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM (2000) Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20:1262–1275CrossRefPubMedGoogle Scholar
  27. 27.
    Mohar DS, Salcedo J, Hoang KC et al (2014) Epicardial adipose tissue volume as a marker of coronary artery disease severity in patients with diabetes independent of coronary artery calcium: findings from the CTRAD study. Diabetes Res Clin Pract 106:228–235CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Wang CP, Hsu HL, Hung WC et al (2009) Increased epicardial adipose tissue (EAT) volume in type 2 diabetes mellitus and association with metabolic syndrome and severity of coronary atherosclerosis. Clin Endocrinol 70:876–882CrossRefGoogle Scholar
  29. 29.
    Iacobellis G, Barbarini G, Letizia C, Barbaro G (2014) Epicardial fat thickness and nonalcoholic fatty liver disease in obese subjects. Obesity (Silver Spring) 22:332–336CrossRefGoogle Scholar
  30. 30.
    Cikim AS, Topal E, Harputluoglu M et al (2007) Epicardial adipose tissue, hepatic steatosis and obesity. J Endocrinol Investig 30:459–464CrossRefGoogle Scholar
  31. 31.
    Psychari SN, Rekleiti N, Papaioannou N et al (2015) Epicardial Fat in Nonalcoholic Fatty Liver Disease: Properties and Relationships With Metabolic Factors, Cardiac Structure, and Cardiac Function. Angiology.  https://doi.org/10.1177/0003319715576672
  32. 32.
    Tang A, Tan J, Sun M et al (2013) Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 267:422–431CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Permutt Z, Le TA, Peterson MR et al (2012) Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther 36:22–29CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Loomba R, Sirlin CB, Ang B et al (2015) Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 61:1239–1250CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Cui J, Heba E, Hernandez C et al (2016) Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: A prospective study. Hepatology 63:453–461CrossRefPubMedGoogle Scholar
  36. 36.
    Dulai PS, Sirlin CB, Loomba R (2016) MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. J Hepatol. in pressGoogle Scholar
  37. 37.
    Doycheva I, Cui J, Nguyen P et al (2016) Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther 43:83–95CrossRefPubMedGoogle Scholar
  38. 38.
    Loomba R, Wolfson T, Ang B et al (2014) Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology 60:1920–1928CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Noureddin M, Lam J, Peterson MR et al (2013) Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 58:1930–1940CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Loomba R, Cui J, Wolfson T et al (2016) Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD: A Prospective Study. Am J Gastroenterol 111:986–994CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R (1990) Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15:827–832CrossRefPubMedGoogle Scholar
  42. 42.
    Dey D, Nakazato R, Li D, Berman DS (2012) Epicardial and thoracic fat - Noninvasive measurement and clinical implications. Cardiovasc Diagn Ther 2:85–93PubMedPubMedCentralGoogle Scholar
  43. 43.
    Grundy SM, Cleeman JI, Daniels SR et al (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752CrossRefPubMedGoogle Scholar
  44. 44.
    Graner M, Nyman K, Siren R et al (2015) Ectopic fat depots and left ventricular function in nondiabetic men with nonalcoholic fatty liver disease. Circ Cardiovasc Imaging 8Google Scholar
  45. 45.
    Clark JM, Brancati FL, Diehl AM (2002) Nonalcoholic fatty liver disease. Gastroenterology 122:1649–1657CrossRefPubMedGoogle Scholar
  46. 46.
    Dong MH, Bettencourt R, Brenner DA, Barrett-Connor E, Loomba R (2012) Serum levels of alanine aminotransferase decrease with age in longitudinal analysis. Clin Gastroenterol Hepatol 10(285-290):e281Google Scholar
  47. 47.
    Adams LA, Sanderson S, Lindor KD, Angulo P (2005) The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42:132–138CrossRefPubMedGoogle Scholar
  48. 48.
    Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C (2004) Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40:820–826PubMedGoogle Scholar
  49. 49.
    Mahabadi AA, Lehmann N, Kalsch H et al (2014) Association of epicardial adipose tissue with progression of coronary artery calcification is more pronounced in the early phase of atherosclerosis: results from the Heinz Nixdorf recall study. JACC Cardiovasc Imaging 7:909–916CrossRefPubMedGoogle Scholar

Copyright information

© European Society of Radiology 2017

Authors and Affiliations

  • Sharon S. Brouha
    • 1
  • Phirum Nguyen
    • 2
    • 3
  • Ricki Bettencourt
    • 2
    • 3
    • 4
  • Claude B. Sirlin
    • 3
  • Rohit Loomba
    • 2
    • 3
    • 4
  1. 1.Department of RadiologyUniversity of California at San DiegoSan DiegoUSA
  2. 2.NAFLD Research Center and Division of Gastroenterology, Department of MedicineUniversity of CaliforniaLa JollaUSA
  3. 3.Liver Imaging Group, Department of RadiologyUniversity of CaliforniaLa JollaUSA
  4. 4.Division of Epidemiology, Department of Family Medicine and Public HealthUniversity of CaliforniaLa JollaUSA

Personalised recommendations